Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 40, Issue 3, 2015, Pages 267-276

  Kumar, K Kishore ^a,b   Priyanka, Leena ^b   Gnananath, K ^b   Babu, P Ravindra ^b,c   Sujatha, S ^b,d  

^a Malla Reddy College of Pharmacy   (India)

^b Vaagdevi College of Pharmacy   (India)

^c KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^d Maisammaguda Dhulapally   (India)

Author keywords

Apigenin; CYP3A4; Non everted sacs; P glycoprotein; Paclitaxel; Rutin

Indexed keywords

APIGENIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; RUTOSIDE; VERAPAMIL; CYTOCHROME P450 3A;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; AREA UNDER THE MOMENT CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; INCUBATION TEMPERATURE; INCUBATION TIME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ANIMAL; BIOAVAILABILITY; HALF LIFE TIME; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; APIGENIN; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HALF-LIFE; MALE; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, WISTAR; RUTIN;

EID: 84940593205     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0203-z     Document Type: Article

References (43)

1. Bansal T, Jaggi M, Khar RK, Talegaonkar S (2009) Emerging significance of flavonoids as p-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharmaceut Sci 12(1):46-78
2. Berg S, Tolcher A, ÒShaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM (1995) Effect of R verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13:2039-2042
3. Byung CC, Jun SC, Hyo KH (2006) Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharma 323:81-85
4. Chan HJ, Ji YL, Chul HC, Chang JK (2007) Anti-asthmatic action of quercetin and rutin in conscious guinea-pigs challenged with aerosolized ovalbumin. Arch Pharm Res 30:1599-1607
5. Choi JS, Choi HK, Shin SC (2004) Enhanced bioavailability of paclitaxel after oral co-administration with flavone in rats. Int J Pharm 275:165-170
6. Conseil G, Baubichon-Cortary H, Dayan G, Jault JM, di Barron K, Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid binding sites on mouse P-glycoprotein. Proc Natl Acad Sci 95:9831-9836
7. Critchfield JW, Welsh CJ, Phang JM (1994) Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48:1437-1445
8. De Mario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557-2567
9. Eberl S, Renner B, Neubert A (2007) Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46:1039-1049
10. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH (2005) Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19:342-353
11. Fukuda K, Ohta T, Oshima Y (1997) Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396
12. Geahlen RL, Koonchanok NM, McLaughlin JL, Pratt DE (1989) Inhibition of protein-tyrosine kinase activity by flavonoids and related compounds. J Nat Prod 52:982-986
13. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong AN (2006) Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch Pharm Res 29:633-644
14. Ho PC, Saville DJ, Wanwimolruk S (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4:217-227
15. Jin BH, Qian LB, Chen S, Li J, Wang HP, Bruce IC, Lin J, Xia Q (2009) Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress. Eur J Pharmacol 616:200-205
16. Joseph TD, Robert LT, Gary CY (2011) Pharmacotherapy: a phathophysiologic approach, 8th edn. Mc Graw Hill, New York, pp 2205-2206
17. Jun SC, Byung WJ (2004) Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharma 280:221-227
18. Jun SC, Sang CS (2005) Enhanced paclitaxel bioavailability after oral co-administration of paclitaxel prodrug with naringin to rats. Int J Pharm 292:149-156
19. Jun SC, Xiuguo L (2005) The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharma Sci 24:95-100
20. Jun SC, Hoo KC, Sang CS (2004) Enhanced bioavailability of paclitaxel after oral co-administration with flavone in rats. Int J Pharma 275:165-170
21. Kamalakkannan N, Prince PSM (2006) Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues. Mol Cell Biochem 293:211-219
22. Kimura Y, Ito H, Ohnishi R (2010) Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 48:429-435
23. La Casa C, Villegas I, Alarcon De la Lastra C, Motilva V, Martin Calero MJ (2006) Evidence for protective and antioxidant properties of rutin, a natural flavone, against ethanol induced gastric lesions. J Ethnopharmacol 71:45-53
24. Li X, Choi JS (2007) Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 337:188-193
25. Li X, Choi JS (2009) Effects of quercetin on the pharmacokinetics of etoposide after oral and intravenous administration of etoposide in rats. Anticancer Res 29:1411-1416
26. Li Xiuguo, Jun SC (2007) Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 337:188-193
27. Li X, Yun JK, Choi JS (2007) Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 28:151-156
28. Meerum Terwogt JM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Schellens JHM (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352:285-289
29. Nguyen H, Zhang S, Morris ME (2003) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250-257
30. Peter H, Pavel T, Marie S (2002) Flavonoids-potent and versatile biologically active compounds interacting with cytochrome P450. Chemico-biol Interact 139:1-12
31. Piao Y, Shin SC, Choi JS (2008) Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 29:245-249
32. Ravindra BP, Naveen BK, Haroled PL, Rajesh K, Jawahar BP (2013) Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Deve Indu Pharm 39:873-879
33. Rosemary CP, Andrew JM, Uraina SC, Gary JB (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94:293-304
34. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15
35. Sam SK, Ji YL, Yoo KC, Gap SK, Byung HH (2004) Neuroprotective effects of flavones on hydrogen peroxide-induced apoptosis in SH-SY5Y neuroblostoma cells. Bioorg Med Chem Lett 14:2261-2264
36. Shih HF, Yu CH, Pei DLC (2005) Pharmacokinetic and pharmacodynamic interactions of morin and cyclosporine. Toxicol Appl Pharmacol 205:65-70
37. Shukla S, Gupta S (2009) Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study. Mol Carcinog 48:243-252
38. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Bejinen JW, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci 4:2031-2035
39. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs 20:1-6
40. Van AJ, Van TO, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183
41. Venkatesh RC, Ravindra BP, Siva RC, Benito J, Maheswari C (2013) Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Deve Indu Pharm 39:865-872
42. Wang LZ, Ho PC, Lee HS, Vaddi HK, Chan YW, Yung CS (2003) Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. J Pharm Biomed Anal 31(2):283-289
43. Woo JS, Lee CH, Shim CK, Hwang SJ (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30